Implications of COVID-19 on statistical design and analyses of clinical studies
This whitepaper discusses the major statistical principles that need to be considered when assessing the impact on trials due to the disruptions caused by COVID-19 including the role of Data Monitoring Committees (DMCs) and interim analyses for risk assessments and how to handle missing or delayed assessments in analyses and reports.
Whitepaper
Learn about the Implications of COVID-19 on statistical design and analyses of clinical studies.
Biostatistics
Innovative clinical trial designs that take advantage of our in depth statistical expertise.